



For Immediate Release

Aquinox Pharmaceuticals to Present at Canaccord Genuity 34th Annual Growth Conference

Vancouver, British Columbia, August 6, 2014 – Aquinox Pharmaceuticals, Inc. (“Aquinox”, NASDAQ: AQXP), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that David Main, Aquinox’s Chief Executive Officer, will present at the upcoming Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14 at 3:00 PM Eastern Time. The conference will take place at the InterContinental Boston in Boston, MA.

A live audio webcast and archive of the event will be available at <http://wsw.com/webcast/canaccord14/aqxp>. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of Aquinox’s website for at least two weeks following the presentation.

The corporate overview being presented will be available at www.aqxpharma.com.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc. is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5’-phosphatase 1 (“SHIP1”) for the treatment of inflammatory disease and cancer. For more information please visit www.aqxpharma.com.

Contact Info:

Brendan Payne

Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com

Bianca Nery

Senior Account Executive
MacDougall Biomedical Communications
650.339.7533
aquinox@macbiocom.com

AQUINOX PHARMACEUTICALS INC.
Suite 450 - 887 Great Northern Way
Vancouver, BC, Canada V5T 4T5

Tel 604.629.9223
Fax 778.331.4486
Web www.aqxpharma.com